These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 8899109

  • 1. Monoclonal antibody therapy of inflammatory bowel disease.
    van Deventer SJ, Camoglio L.
    Aliment Pharmacol Ther; 1996; 10 Suppl 2():107-11; discussion 112. PubMed ID: 8899109
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibody therapy of inflammatory bowel disease.
    van Deventer SJ, Camoglio L.
    Pharm World Sci; 1997 Apr; 19(2):55-9. PubMed ID: 9151342
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody].
    Asakura H.
    Nihon Rinsho; 2002 Mar; 60(3):531-8. PubMed ID: 11904969
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N, Chaki R, Mandal V, Lin GD, Mandal SC.
    Int Rev Immunol; 2010 Mar; 29(1):4-37. PubMed ID: 20100080
    [Abstract] [Full Text] [Related]

  • 5. [Standards, perspectives and limits of conservative therapy of chronic inflammatory bowel diseases].
    Rogler G, Andus T, Schölmerich J.
    Zentralbl Chir; 1998 Mar; 123(4):316-24. PubMed ID: 9622888
    [Abstract] [Full Text] [Related]

  • 6. Current dilemmas in the management of inflammatory bowel disease.
    Rutgeerts P.
    Eur J Surg Suppl; 2002 Mar; (587):58-61. PubMed ID: 16144202
    [Abstract] [Full Text] [Related]

  • 7. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy].
    van Deventer SJ.
    Ned Tijdschr Geneeskd; 1997 Oct 11; 141(41):1956-9. PubMed ID: 9550744
    [Abstract] [Full Text] [Related]

  • 8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.
    Dig Liver Dis; 2005 Jun 11; 37(6):407-17. PubMed ID: 15893279
    [Abstract] [Full Text] [Related]

  • 9. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P, Van Assche G, Vermeire S.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):451-63. PubMed ID: 16441465
    [Abstract] [Full Text] [Related]

  • 10. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?
    Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R.
    J Clin Apher; 2005 Oct 15; 20(3):171-84. PubMed ID: 15892107
    [Abstract] [Full Text] [Related]

  • 11. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.
    Hibi T, Inoue N, Ogata H, Naganuma M.
    J Gastroenterol; 2003 Mar 15; 38 Suppl 15():36-42. PubMed ID: 12698869
    [Abstract] [Full Text] [Related]

  • 12. [Biologic therapy of inflammatory bowel disease].
    Baumgart DC, Wiedenmann B, Dignass AU.
    Z Gastroenterol; 2003 Oct 15; 41(10):1017-32. PubMed ID: 14562200
    [Abstract] [Full Text] [Related]

  • 13. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A.
    Aliment Pharmacol Ther; 2004 Nov 15; 20(10):1143-52. PubMed ID: 15569117
    [Abstract] [Full Text] [Related]

  • 14. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Aug 01; 20(3):303-10. PubMed ID: 15274667
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapy of Crohn's disease.
    van Montfrans C, Camoglio L, van Deventer SJ.
    Mediators Inflamm; 1998 Aug 01; 7(3):149-52. PubMed ID: 9705600
    [Abstract] [Full Text] [Related]

  • 16. Paediatric inflammatory bowel disease in New Zealand.
    Yap J, Wesley A, Mouat S, Chin S.
    N Z Med J; 2008 Oct 03; 121(1283):19-34. PubMed ID: 18841182
    [Abstract] [Full Text] [Related]

  • 17. Alterations in serum anti-alpha-galactosyl antibodies in patients with Crohn's disease and ulcerative colitis.
    D'Alessandro M, Mariani P, Lomanto D, Bachetoni A, Speranza V.
    Clin Immunol; 2002 Apr 03; 103(1):63-8. PubMed ID: 11987986
    [Abstract] [Full Text] [Related]

  • 18. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
    Dejaco C, Gasché C, Reinisch W, Moser G, Novacek G, Tillinger W, Vogelsang H, Gangl A.
    Wien Klin Wochenschr; 1998 Sep 04; 110(16):579-84. PubMed ID: 9782579
    [Abstract] [Full Text] [Related]

  • 19. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
    Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA, Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
    Aliment Pharmacol Ther; 2004 Dec 04; 20(11-12):1347-52. PubMed ID: 15606397
    [Abstract] [Full Text] [Related]

  • 20. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD).
    Heresbach D, Sémana G, Gosselin M, Bretagne MG.
    Eur Cytokine Netw; 1999 Mar 04; 10(1):7-15. PubMed ID: 10210767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.